Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9H9J2
UPID:
RM44_HUMAN
Alternative names:
39S ribosomal protein L44, mitochondrial
Alternative UPACC:
Q9H9J2; Q53S16; Q6IA62; Q9H821
Background:
Large ribosomal subunit protein mL44, also known as 39S ribosomal protein L44, mitochondrial, plays a crucial role in the 39S subunit of mitochondrial ribosome. It is instrumental in the assembly and stability of nascent mitochondrial polypeptides exiting the ribosome, highlighting its importance in mitochondrial protein synthesis.
Therapeutic significance:
The protein is linked to Combined oxidative phosphorylation deficiency 16, a mitochondrial disorder characterized by symptoms such as hypertrophic cardiomyopathy and liver steatosis. This association underscores the potential of targeting mL44 in therapeutic strategies aimed at mitigating the effects of this disease.